Blog • P95 | Vaccines and Infectious Disease CRO

Vaccination Programmes Book On Epidemiology, and Monitoring

Dec 6 | News

Our P95 colleague Kaatje Bollaerts is excited to announce that the book ‘Vaccination Programmes | Epidemiology, Monitoring, Evaluation’ by Susan Hahné, Kaatje Bollaerts, and Paddy Farrington is now available to all to view and use online through a new open-access grant provided by CEPI.

OnQ joins the P95 family

Oct 16 | Press

P95 has signed an agreement to merge OnQ Research (“OnQ”) into P95. The transaction, furthers P95’s goal of becoming the leading global, vaccine-focused CRO. P95 now has unparalleled expertise conducting research in emerging geographies on the infectious diseases which could possibly drive a future pandemic.

P95 Attends Infectology Congress in Buenos Aires

Sep 18 | Events

Last week, P95 attended for the first time, the Congreso de Infectología 2023 organized by Asociación Panamericana de Infectología (API) and Sociedad Argentina de Infectología (SADI), which took place in Buenos Aires, Argentina.
This congress gathered renowned experts from the field of infectology, who shared lessons learnt and debated the most pressing and current topics on this topic.
More about the congress: https://www.congresosadi.com/

P95 exhibits at Bio Asia Pacific 2023

Sep 18 | Events

P95 is proud to be an official exhibitor at this year’s Bio Asia Pacific in Bangkok. Bio Asia Pacific is one of the leading conferences and exhibitions for Biotechnology, Life Sciences and Smart Health in Southeast Asia. This year we had the opportunity to present a bit more about our company and our recently created Sout East Asia office in Bangkok by our Regional Director South East Asia, Tharinee Sakhakorn.

Enabling the evaluation of COVID-19 vaccines with correlates of protection

Aug 18 | Publications

In February 2023, a meeting about correlates of protection (CoPs) against COVID-19 was organized by the International Alliance for Biological Standardization, the European Plotkin Institute for Vaccinology, and Vaccinopolis. The meeting aimed at reviewing the evidence, drawing conclusions, and identifying knowledge gaps.

COVIDRIVE: AZD1222 vaccine effectiveness against hospitalisation

Aug 3 | Publications

Vaccine effectiveness (VE) studies with long-term follow-up are needed to understand durability of protection against severe COVID-19 outcomes conferred by primary-series vaccination in individuals not receiving boosters. COVIDRIVE is a European public-private partnership evaluating brand-specific vaccine effectiveness (VE). We report a prespecified interim analysis of primary-series AZD1222 (ChAdOx1 nCoV-19) VE.

P95 BV and Ampersand Capital Partners

May 2 | Press

Leuven, Belgium, May 2nd, 2023 – P95 BV, a global provider of epidemiology and clinical research solutions with a focus on vaccines and infectious diseases, today announced a majority recapitalization by Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the life science and healthcare sectors. Ampersand’s investment will support the growth of P95’s core business and fund the expansion of its CRO services supporting the vaccine and infectious disease end-markets. As part of the transaction, P95 also announced the appointment of Benoit Bouche as Chairman of the company’s Board of Directors.

Lyme Disease Publications

Apr 24 | Publications

P95 has collaborated in a large review study about Lyme disease. This study has involved databases/surveillance and systematic reviews focusing on Lyme disease incidence, epidemiology, hospitalization, and clinical manifestations, among other outcomes, in different regions of the World.